Plus Therapeutics将参加HC的炉边聊天温赖特第27届年度全球投资会议

HOUSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it will participate in the H.C. Wainwright 27^th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel.

Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer will participate in a fireside chat with Sean Lee, VP of Equity Research at H.C. Wainwright. The fireside chat will be available on demand beginning Friday, September 5 at 7:00am ET for registered investors of the conference. To request a one-on-one meeting with Dr. Hedrick and to register for the conference, click below:
https://hcwevents.com/annualconference/

About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://plustherapeutics.com/.

Investor Contact
CORE IR
investor@plustherapeutics.com